Hiret 2016.

Methods	Phase II randomised study
Participants	People with KRAS WT mCRC whose disease progressed on first‐line treatment with fluoropyrimidine‐based chemotherapy and bevacizumab
Interventions	mFOLFOX or FOLFIRI (the one not used in first‐line treatment) with bevacizumab vs mFOLFOX or FOLFIRI (the one not used in first‐line treatment) with cetuximab
Outcomes	Primary endpoint: PFS at 4 months. Secondary endpoints: response rate, median PFS, OS, safety, quality of life (EORTC QLQ‐C30)
Notes